Keßler Real Estate Solutions GmbH Revenue and Competitors
Estimated Revenue & Valuation
- Keßler Real Estate Solutions GmbH's estimated annual revenue is currently $1.4M per year.
- Keßler Real Estate Solutions GmbH's estimated revenue per employee is $87,000
Employee Data
- Keßler Real Estate Solutions GmbH has 16 Employees.
Keßler Real Estate Solutions GmbH's People
Name | Title | Email/Phone |
---|
Keßler Real Estate Solutions GmbH Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $83.8M | 455 | 7% | $131.3M | N/A |
#2 | $12.2M | 84 | 15% | N/A | N/A |
#3 | $7.6M | 58 | 2% | N/A | N/A |
#4 | $4.6M | 40 | 25% | N/A | N/A |
#5 | $17.5M | 121 | -29% | N/A | N/A |
#6 | $81.9M | 452 | 3% | N/A | N/A |
#7 | $145.6M | 717 | 9% | N/A | N/A |
#8 | $38.8M | 243 | 34% | N/A | N/A |
#9 | $8.7M | 67 | 34% | N/A | N/A |
#10 | $1.5M | 17 | -61% | N/A | N/A |
What Is Keßler Real Estate Solutions GmbH?
N/A
Total Funding
16
Number of Employees
$1.4M
Revenue (est)
N/A
Employee Growth %
N/A
Valuation
N/A
Accelerator
Keßler Real Estate Solutions GmbH News
2022-03-22 - 2021 PTAB Year in Review: Analysis & Trends: Discretionary ...
On March 24, 2020, the PTAB designated Advanced Bionics, LLC v. Med-El Elektromedizinische Geräte GMBH1 and two sections of Oticon Medical AB v.
2022-03-22 - 2021 PTAB Year in Review: Analysis & Trends: Standard ...
Tim Pohlmann, SEP Litigation Trends: What Does the Data Say? 1 (IPlytics GmbH ed., 2021). 4. Report: Litigation Landscape of Standard-Essential...
2022-03-22 - 2021 PTAB Year in Review: Analysis & Trends: Is the Tide ...
The so-called Lead Compound Analysis is the primary legal framework for assessing chemical obviousness. Despite the USPTO Patent Trial and...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $3.1M | 16 | -11% | N/A |
#2 | $1.6M | 18 | -14% | N/A |
#3 | $2.1M | 21 | N/A | N/A |
#4 | $5.5M | 29 | 4% | N/A |
#5 | N/A | 30 | 7% | N/A |